Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related 		KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Acute myeloid leukemia 💬
 1件: KIT 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
2 Acute myeloid leukemia 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
3 Acute myeloid leukemia 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
4 Adherens junction 💬
 1件: FGFR1 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
5 Adherens junction 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
6 Adipocytokine signaling pathway 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
7 Adipocytokine signaling pathway 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
8 Adrenergic signaling in cardiomyocytes 💬
 1件: ADRB2 💬 Albuterol 💬 Salbutamol 12件:  3 , 11, 12, 13, 49, 85, 86, 89, 111, 113, 256, 299 💬
9 Alzheimer disease 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
10 Alzheimer disease 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
11 Alzheimer disease 💬
 1件: PTGS2 💬 Celecoxib 💬 Celecoxib 10件:  2 ,  3 , 34, 46, 70, 89, 107, 161, 171, 271 💬
12 AMPK signaling pathway 💬
 1件: HMGCR 💬 Simvastatin 💬 Simvastatin 21件:  6 , 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 💬
13 AMPK signaling pathway 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
14 AMPK signaling pathway 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
15 Amyotrophic lateral sclerosis 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
16 Amyotrophic lateral sclerosis 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
17 Apelin signaling pathway 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
18 Apelin signaling pathway 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
19 Arachidonic acid metabolism 💬
 1件: PTGS2 💬 Celecoxib 💬 Celecoxib 10件:  2 ,  3 , 34, 46, 70, 89, 107, 161, 171, 271 💬
20 Autophagy - animal 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
21 Autophagy - animal 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
22 Autophagy - other 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
23 Autophagy - other 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
24 Axon guidance 💬
 1件: ABL1 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
25 Axon guidance 💬
 2件: ABL1, SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
26 Bacterial invasion of epithelial cells 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
27 Bile secretion 💬
 1件: HMGCR 💬 Simvastatin 💬 Simvastatin 21件:  6 , 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 💬
28 Bladder cancer 💬
 1件: FGFR3 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
29 Bladder cancer 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
30 Breast cancer 💬
 2件: FGFR1, FLT4 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
31 Breast cancer 💬
 1件: KIT 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
32 Breast cancer 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
33 Breast cancer 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
34 C-type lectin receptor signaling pathway 💬
 1件: PTGS2 💬 Celecoxib 💬 Celecoxib 10件:  2 ,  3 , 34, 46, 70, 89, 107, 161, 171, 271 💬
35 C-type lectin receptor signaling pathway 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
36 Calcium signaling pathway 💬
 1件: ADRB2 💬 Albuterol 💬 Salbutamol 12件:  3 , 11, 12, 13, 49, 85, 86, 89, 111, 113, 256, 299 💬
37 Calcium signaling pathway 💬
 8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
38 Calcium signaling pathway 💬
 1件: HRH1 💬 Loratadine 💬 Loratadine 4件: 13, 46, 89, 98 💬
39 Calcium signaling pathway 💬
 1件: PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
40 cAMP signaling pathway 💬
 1件: ADRB2 💬 Albuterol 💬 Salbutamol 12件:  3 , 11, 12, 13, 49, 85, 86, 89, 111, 113, 256, 299 💬
41 cAMP signaling pathway 💬
 1件: SSTR2 💬 Octreotide 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
42 Cell cycle 💬
 1件: ABL1 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
43 Cell cycle 💬
 1件: ABL1 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
44 Cellular senescence 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
45 Cellular senescence 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
46 Central carbon metabolism in cancer 💬
 5件: FGFR1, FGFR2, FGFR3, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
47 Central carbon metabolism in cancer 💬
 2件: KIT, PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
48 Central carbon metabolism in cancer 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
49 Central carbon metabolism in cancer 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
50 cGMP-PKG signaling pathway 💬
 1件: ADRB2 💬 Albuterol 💬 Salbutamol 12件:  3 , 11, 12, 13, 49, 85, 86, 89, 111, 113, 256, 299 💬
51 Chemical carcinogenesis - DNA adducts 💬
 1件: PTGS2 💬 Celecoxib 💬 Celecoxib 10件:  2 ,  3 , 34, 46, 70, 89, 107, 161, 171, 271 💬
52 Chemical carcinogenesis - reactive oxygen species 💬
 1件: ABL1 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
53 Chemical carcinogenesis - reactive oxygen species 💬
 2件: ABL1, SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
54 Chemical carcinogenesis - receptor activation 💬
 1件: ADRB2 💬 Albuterol 💬 Salbutamol 12件:  3 , 11, 12, 13, 49, 85, 86, 89, 111, 113, 256, 299 💬
55 Chemical carcinogenesis - receptor activation 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
56 Chemical carcinogenesis - receptor activation 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
57 Chemical carcinogenesis - receptor activation 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
58 Chemokine signaling pathway 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
59 Choline metabolism in cancer 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
60 Choline metabolism in cancer 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
61 Choline metabolism in cancer 💬
 1件: PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
62 Choline metabolism in cancer 💬
 2件: PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
63 Chronic myeloid leukemia 💬
 1件: ABL1 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
64 Chronic myeloid leukemia 💬
 1件: ABL1 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
65 Colorectal cancer 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
66 Colorectal cancer 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
67 Diabetic cardiomyopathy 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
68 Diabetic cardiomyopathy 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
69 EGFR tyrosine kinase inhibitor resistance 💬
 5件: FGFR2, FGFR3, KDR, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
70 EGFR tyrosine kinase inhibitor resistance 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
71 EGFR tyrosine kinase inhibitor resistance 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
72 EGFR tyrosine kinase inhibitor resistance 💬
 1件: PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
73 EGFR tyrosine kinase inhibitor resistance 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
74 Endocrine resistance 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
75 Endocrine resistance 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
76 Endocrine resistance 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
77 Endocytosis 💬
 3件: FGFR2, FGFR3, PDGFRA 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
78 Endocytosis 💬
 1件: PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
79 Endocytosis 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
80 Epithelial cell signaling in Helicobacter pylori infection 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
81 ErbB signaling pathway 💬
 1件: ABL1 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
82 ErbB signaling pathway 💬
 2件: ABL1, SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
83 ErbB signaling pathway 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
84 ErbB signaling pathway 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
85 Estrogen signaling pathway 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
86 Fluid shear stress and atherosclerosis 💬
 1件: KDR 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
87 Fluid shear stress and atherosclerosis 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
88 Focal adhesion 💬
 5件: FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
89 Focal adhesion 💬
 1件: PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
90 Focal adhesion 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
91 GABAergic synapse 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
92 Gap junction 💬
 1件: PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
93 Gap junction 💬
 2件: PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
94 Gap junction 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
95 Gastric acid secretion 💬
 1件: SSTR2 💬 Octreotide 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
96 Gastric cancer 💬
 1件: FGFR2 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
97 Gastric cancer 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
98 Gastric cancer 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
99 Glioma 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
100 Glioma 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
101 Glioma 💬
 1件: PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
102 Glioma 💬
 2件: PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
103 GnRH signaling pathway 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
104 Growth hormone synthesis, secretion and action 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
105 Growth hormone synthesis, secretion and action 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
106 Growth hormone synthesis, secretion and action 💬
 1件: SSTR2 💬 Octreotide 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
107 Hematopoietic cell lineage 💬
 1件: KIT 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
108 Hepatitis B 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
109 Hepatocellular carcinoma 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
110 Hepatocellular carcinoma 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
111 Herpes simplex virus 1 infection 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
112 Herpes simplex virus 1 infection 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
113 Herpes simplex virus 1 infection 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
114 HIF-1 signaling pathway 💬
 1件: FLT1 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
115 HIF-1 signaling pathway 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
116 HIF-1 signaling pathway 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
117 Human cytomegalovirus infection 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
118 Human cytomegalovirus infection 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
119 Human cytomegalovirus infection 💬
 1件: PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
120 Human cytomegalovirus infection 💬
 1件: PDGFRA 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
121 Human cytomegalovirus infection 💬
 1件: PTGS2 💬 Celecoxib 💬 Celecoxib 10件:  2 ,  3 , 34, 46, 70, 89, 107, 161, 171, 271 💬
122 Human cytomegalovirus infection 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
123 Human immunodeficiency virus 1 infection 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
124 Human immunodeficiency virus 1 infection 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
125 Human papillomavirus infection 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
126 Human papillomavirus infection 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
127 Human papillomavirus infection 💬
 1件: PDGFRB 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
128 Human papillomavirus infection 💬
 1件: PTGS2 💬 Celecoxib 💬 Celecoxib 10件:  2 ,  3 , 34, 46, 70, 89, 107, 161, 171, 271 💬
129 Huntington disease 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
130 Huntington disease 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
131 IL-17 signaling pathway 💬
 1件: PTGS2 💬 Celecoxib 💬 Celecoxib 10件:  2 ,  3 , 34, 46, 70, 89, 107, 161, 171, 271 💬
132 Inflammatory mediator regulation of TRP channels 💬
 1件: HRH1 💬 Loratadine 💬 Loratadine 4件: 13, 46, 89, 98 💬
133 Inflammatory mediator regulation of TRP channels 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
134 Insulin resistance 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
135 Insulin resistance 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
136 Insulin signaling pathway 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
137 Insulin signaling pathway 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
138 JAK-STAT signaling pathway 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
139 JAK-STAT signaling pathway 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
140 JAK-STAT signaling pathway 💬
 1件: PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
141 JAK-STAT signaling pathway 💬
 2件: PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
142 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
143 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
144 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: PTGS2 💬 Celecoxib 💬 Celecoxib 10件:  2 ,  3 , 34, 46, 70, 89, 107, 161, 171, 271 💬
145 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
146 Leishmaniasis 💬
 1件: PTGS2 💬 Celecoxib 💬 Celecoxib 10件:  2 ,  3 , 34, 46, 70, 89, 107, 161, 171, 271 💬
147 Lipid and atherosclerosis 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
148 Longevity regulating pathway 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
149 Longevity regulating pathway 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
150 Longevity regulating pathway - multiple species 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
151 Longevity regulating pathway - multiple species 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
152 MAPK signaling pathway 💬
 8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
153 MAPK signaling pathway 💬
 2件: KIT, PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
154 Melanogenesis 💬
 1件: KIT 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
155 Melanoma 💬
 3件: FGFR1, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
156 Melanoma 💬
 1件: PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
157 Metabolic pathways 💬
 1件: CYP19A1 💬 Letrozole 💬 Letrozole 2件: 81, 89 💬
158 Metabolic pathways 💬
 1件: HMGCR 💬 Simvastatin 💬 Simvastatin 21件:  6 , 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 💬
159 Metabolic pathways 💬
 1件: PTGS2 💬 Celecoxib 💬 Celecoxib 10件:  2 ,  3 , 34, 46, 70, 89, 107, 161, 171, 271 💬
160 MicroRNAs in cancer 💬
 1件: ABL1 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
161 MicroRNAs in cancer 💬
 2件: ABL1, PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
162 MicroRNAs in cancer 💬
 3件: FGFR3, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
163 MicroRNAs in cancer 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
164 MicroRNAs in cancer 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
165 MicroRNAs in cancer 💬
 1件: PTGS2 💬 Celecoxib 💬 Celecoxib 10件:  2 ,  3 , 34, 46, 70, 89, 107, 161, 171, 271 💬
166 Mitophagy - animal 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
167 mTOR signaling pathway 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
168 mTOR signaling pathway 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
169 Neuroactive ligand-receptor interaction 💬
 1件: ADRB2 💬 Albuterol 💬 Salbutamol 12件:  3 , 11, 12, 13, 49, 85, 86, 89, 111, 113, 256, 299 💬
170 Neuroactive ligand-receptor interaction 💬
 1件: HRH1 💬 Loratadine 💬 Loratadine 4件: 13, 46, 89, 98 💬
171 Neuroactive ligand-receptor interaction 💬
 1件: SSTR2 💬 Octreotide 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
172 Neurotrophin signaling pathway 💬
 1件: ABL1 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
173 Neurotrophin signaling pathway 💬
 1件: ABL1 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
174 Neutrophil extracellular trap formation 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
175 Neutrophil extracellular trap formation 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
176 Neutrophil extracellular trap formation 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
177 NF-kappa B signaling pathway 💬
 1件: PTGS2 💬 Celecoxib 💬 Celecoxib 10件:  2 ,  3 , 34, 46, 70, 89, 107, 161, 171, 271 💬
178 Ovarian steroidogenesis 💬
 1件: CYP19A1 💬 Letrozole 💬 Letrozole 2件: 81, 89 💬
179 Ovarian steroidogenesis 💬
 1件: PTGS2 💬 Celecoxib 💬 Celecoxib 10件:  2 ,  3 , 34, 46, 70, 89, 107, 161, 171, 271 💬
180 Oxytocin signaling pathway 💬
 1件: PTGS2 💬 Celecoxib 💬 Celecoxib 10件:  2 ,  3 , 34, 46, 70, 89, 107, 161, 171, 271 💬
181 Oxytocin signaling pathway 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
182 Pancreatic cancer 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
183 Pancreatic cancer 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
184 Parathyroid hormone synthesis, secretion and action 💬
 1件: FGFR1 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
185 Pathogenic Escherichia coli infection 💬
 1件: ABL1 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
186 Pathogenic Escherichia coli infection 💬
 2件: ABL1, SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
187 Pathways in cancer 💬
 1件: ABL1 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
188 Pathways in cancer 💬
 3件: ABL1, KIT, PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
189 Pathways in cancer 💬
 6件: FGFR1, FGFR2, FGFR3, FLT4, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
190 Pathways in cancer 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
191 Pathways in cancer 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
192 Pathways in cancer 💬
 1件: PTGS2 💬 Celecoxib 💬 Celecoxib 10件:  2 ,  3 , 34, 46, 70, 89, 107, 161, 171, 271 💬
193 Pathways of neurodegeneration - multiple diseases 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
194 Pathways of neurodegeneration - multiple diseases 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
195 Pathways of neurodegeneration - multiple diseases 💬
 1件: PTGS2 💬 Celecoxib 💬 Celecoxib 10件:  2 ,  3 , 34, 46, 70, 89, 107, 161, 171, 271 💬
196 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
197 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
198 Phospholipase D signaling pathway 💬
 2件: KIT, PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
199 Phospholipase D signaling pathway 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
200 Phospholipase D signaling pathway 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
201 Phospholipase D signaling pathway 💬
 2件: PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
202 PI3K-Akt signaling pathway 💬
 8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
203 PI3K-Akt signaling pathway 💬
 2件: KIT, PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
204 PI3K-Akt signaling pathway 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
205 PI3K-Akt signaling pathway 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
206 Platelet activation 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
207 Prolactin signaling pathway 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
208 Prostate cancer 💬
 4件: FGFR1, FGFR2, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
209 Prostate cancer 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
210 Prostate cancer 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
211 Prostate cancer 💬
 1件: PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
212 Proteoglycans in cancer 💬
 2件: FGFR1, KDR 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
213 Proteoglycans in cancer 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
214 Proteoglycans in cancer 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
215 Proteoglycans in cancer 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
216 Rap1 signaling pathway 💬
 8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
217 Rap1 signaling pathway 💬
 2件: KIT, PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
218 Rap1 signaling pathway 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
219 Ras signaling pathway 💬
 1件: ABL1 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
220 Ras signaling pathway 💬
 3件: ABL1, KIT, PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
221 Ras signaling pathway 💬
 8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
222 Regulation of actin cytoskeleton 💬
 5件: FGFR1, FGFR2, FGFR3, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
223 Regulation of actin cytoskeleton 💬
 1件: PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
224 Regulation of actin cytoskeleton 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
225 Regulation of lipolysis in adipocytes 💬
 1件: ADRB2 💬 Albuterol 💬 Salbutamol 12件:  3 , 11, 12, 13, 49, 85, 86, 89, 111, 113, 256, 299 💬
226 Regulation of lipolysis in adipocytes 💬
 1件: PTGS2 💬 Celecoxib 💬 Celecoxib 10件:  2 ,  3 , 34, 46, 70, 89, 107, 161, 171, 271 💬
227 Relaxin signaling pathway 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
228 Renin secretion 💬
 1件: ADRB2 💬 Albuterol 💬 Salbutamol 12件:  3 , 11, 12, 13, 49, 85, 86, 89, 111, 113, 256, 299 💬
229 Retrograde endocannabinoid signaling 💬
 1件: PTGS2 💬 Celecoxib 💬 Celecoxib 10件:  2 ,  3 , 34, 46, 70, 89, 107, 161, 171, 271 💬
230 Rheumatoid arthritis 💬
 1件: FLT1 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
231 Salivary secretion 💬
 1件: ADRB2 💬 Albuterol 💬 Salbutamol 12件:  3 , 11, 12, 13, 49, 85, 86, 89, 111, 113, 256, 299 💬
232 Serotonergic synapse 💬
 1件: PTGS2 💬 Celecoxib 💬 Celecoxib 10件:  2 ,  3 , 34, 46, 70, 89, 107, 161, 171, 271 💬
233 Shigellosis 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
234 Shigellosis 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
235 Shigellosis 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
236 Signaling pathways regulating pluripotency of stem cells 💬
 3件: FGFR1, FGFR2, FGFR3 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
237 Small cell lung cancer 💬
 1件: PTGS2 💬 Celecoxib 💬 Celecoxib 10件:  2 ,  3 , 34, 46, 70, 89, 107, 161, 171, 271 💬
238 Spinocerebellar ataxia 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
239 Spinocerebellar ataxia 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
240 Steroid hormone biosynthesis 💬
 1件: CYP19A1 💬 Letrozole 💬 Letrozole 2件: 81, 89 💬
241 Terpenoid backbone biosynthesis 💬
 1件: HMGCR 💬 Simvastatin 💬 Simvastatin 21件:  6 , 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 💬
242 Th17 cell differentiation 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
243 Th17 cell differentiation 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
244 Thermogenesis 💬
 1件: FGFR1 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
245 Thermogenesis 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
246 Thermogenesis 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
247 Thyroid hormone signaling pathway 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
248 Thyroid hormone signaling pathway 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
249 Thyroid hormone signaling pathway 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
250 Tight junction 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
251 TNF signaling pathway 💬
 1件: PTGS2 💬 Celecoxib 💬 Celecoxib 10件:  2 ,  3 , 34, 46, 70, 89, 107, 161, 171, 271 💬
252 Transcriptional misregulation in cancer 💬
 1件: FLT1 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
253 Tuberculosis 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
254 Type II diabetes mellitus 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
255 Type II diabetes mellitus 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
256 VEGF signaling pathway 💬
 1件: KDR 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
257 VEGF signaling pathway 💬
 1件: PTGS2 💬 Celecoxib 💬 Celecoxib 10件:  2 ,  3 , 34, 46, 70, 89, 107, 161, 171, 271 💬
258 VEGF signaling pathway 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
259 Viral carcinogenesis 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
260 Viral myocarditis 💬
 1件: ABL1 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
261 Viral myocarditis 💬
 1件: ABL1 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
262 Yersinia infection 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬

先頭へ